lactic acid has been researched along with Brucellosis in 14 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Brucellosis: Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In view of treating intracellular Brucella infections, microspheres made of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) were developed as delivery system for the cationic and highly hydrophilic antibiotic gentamicin sulphate." | 7.70 | Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. ( Gamazo, C; Gander, B; Irache, JM; Merkle, HP; Prior, S, 2000) |
| "Gentamicin is used to treat brucellosis, an infectious disease caused by the Brucella species but the drug faces several issues such as low efficacy, instability, low solubility, and toxicity." | 4.31 | Interaction of gentamicin and gentamicin-AOT with poly-(lactide-co-glycolate) in a drug delivery system - density functional theory calculations and molecular dynamics simulation. ( Anwar, J; Duran, S; Moin, ST, 2023) |
| "Drug delivery systems containing gentamicin were studied as a treatment against experimental brucellosis in mice." | 3.74 | Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. ( Blanco-Prieto, MJ; Campanero, MA; Gamazo, C; Lecaroz, MC; Salman, H, 2007) |
| "Neither a single intravenous or intraperitoneal dose of 67 microg of gentamicin per mouse, nor three intraperitoneal doses of 100 microg of gentamicin per mouse, reduced the Brucella infection in the spleen compared with untreated mice 1 and 3 weeks post-treatment." | 3.73 | Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. ( Gamazo, C; Gander, B; Irache, JM; Prior, S, 2005) |
| "The results indicate that PLGA 50:50-microencapsulated gentamicin sulphate may be suitable for efficient drug targeting and delivery to reduce intracellular Brucella infections." | 3.72 | Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. ( Gamazo, C; Gander, B; Irache, JM; Lecároz, C; Prior, S, 2004) |
| "In view of treating intracellular Brucella infections, microspheres made of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) were developed as delivery system for the cationic and highly hydrophilic antibiotic gentamicin sulphate." | 3.70 | Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. ( Gamazo, C; Gander, B; Irache, JM; Merkle, HP; Prior, S, 2000) |
| "Gentamicin formulations reduced Brucella infection in experimentally infected THP-1 monocytes (>2-log10 unit reduction) when using clinically relevant concentrations (18 mg/liter)." | 1.39 | Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice. ( Blanco-Prieto, MJ; Campanero, MÁ; Elizondo, E; Gamazo, C; Gil, AG; Imbuluzqueta, E; Lana, H; Salas, D; Veciana, J; Ventosa, N, 2013) |
| "Gentamicin (GEN) is an aminoglycoside antibiotic with a potent antibacterial activity against a wide variety of bacteria." | 1.37 | Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. ( Blanco-Prieto, MJ; Elizondo, E; Gamazo, C; Imbuluzqueta, E; Moreno-Calvo, E; Veciana, J; Ventosa, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Duran, S | 1 |
| Anwar, J | 1 |
| Moin, ST | 1 |
| Imbuluzqueta, E | 2 |
| Gamazo, C | 9 |
| Lana, H | 1 |
| Campanero, MÁ | 2 |
| Salas, D | 1 |
| Gil, AG | 1 |
| Elizondo, E | 2 |
| Ventosa, N | 2 |
| Veciana, J | 2 |
| Blanco-Prieto, MJ | 4 |
| Singh, D | 2 |
| Goel, D | 1 |
| Bhatnagar, R | 2 |
| Afley, P | 1 |
| Dohre, SK | 1 |
| Prasad, GB | 1 |
| Kumar, S | 1 |
| Somani, VK | 1 |
| Aggarwal, S | 1 |
| Moreno-Calvo, E | 1 |
| Murillo, M | 3 |
| Goñi, MM | 3 |
| Irache, JM | 6 |
| Prior, S | 3 |
| Gander, B | 3 |
| Lecároz, C | 1 |
| Estevan, M | 1 |
| Blasco, JM | 1 |
| Lecaroz, MC | 1 |
| Salman, H | 1 |
| Mavridis, AK | 1 |
| Drosos, AA | 1 |
| Tsolas, O | 1 |
| Moutsopoulos, HM | 1 |
| Merkle, HP | 1 |
14 other studies available for lactic acid and Brucellosis
| Article | Year |
|---|---|
Interaction of gentamicin and gentamicin-AOT with poly-(lactide-co-glycolate) in a drug delivery system - density functional theory calculations and molecular dynamics simulation.
Topics: Anti-Bacterial Agents; Brucellosis; Density Functional Theory; Drug Delivery Systems; Gentamicins; G | 2023 |
Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.
Topics: Animals; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Cell Line; Drug Carriers; Female; | 2013 |
Recombinant L7/L12 protein entrapping PLGA (poly lactide-co-glycolide) micro particles protect BALB/c mice against the virulent B. abortus 544 infection.
Topics: Animals; Antibodies, Bacterial; Brucella abortus; Brucella Vaccine; Brucellosis; Enzyme-Linked Immun | 2015 |
Prediction of T cell epitopes of Brucella abortus and evaluation of their protective role in mice.
Topics: Animals; Brucella abortus; Brucella Vaccine; Brucellosis; Cell Proliferation; Computational Biology; | 2015 |
PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Antigens, Bacterial; Brucella abortus; Bruce | 2015 |
Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections.
Topics: Anti-Infective Agents; Brucella melitensis; Brucellosis; Chemical Precipitation; Crystallization; Di | 2011 |
Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis.
Topics: Bacterial Vaccines; Brucella; Brucellosis; Cell Line; Drug Compounding; Hydrogen-Ion Concentration; | 2002 |
Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes.
Topics: Animals; Anti-Bacterial Agents; Brucella abortus; Brucellosis; Cell Line; Drug Compounding; Gentamic | 2004 |
Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis.
Topics: Animals; Brucella ovis; Brucella Vaccine; Brucellosis; Electrophoresis, Polyacrylamide Gel; Excipien | 2004 |
Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice.
Topics: Animals; Brucella abortus; Brucellosis; Female; Gentamicins; Lactic Acid; Mice; Microspheres; Polygl | 2005 |
Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice.
Topics: Animals; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Disease Models, Animal; Drug Carri | 2007 |
Lactate levels in Brucella arthritis.
Topics: Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Brucellosis; Gout; Humans; Lactates; Lactic | 1984 |
Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections.
Topics: Biocompatible Materials; Brucellosis; Drug Compounding; Gentamicins; Lactic Acid; Microbial Sensitiv | 2000 |
Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity.
Topics: Animals; Antigens, Bacterial; Brucella; Brucella Vaccine; Brucellosis; Drug Carriers; Drug Delivery | 2002 |